Smith & Nephew SNATS (SNN)
(Delayed Data from NYSE)
$28.93 USD
-0.01 (-0.03%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $28.94 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Smith & Nephew (SNN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$32.00 | $33.00 | $31.00 | 10.57% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Smith & Nephew comes to $32.00. The forecasts range from a low of $31.00 to a high of $33.00. The average price target represents an increase of 10.57% from the last closing price of $28.94.
Analyst Price Targets (2 )
Broker Rating
Smith & Nephew currently has an average brokerage recommendation (ABR) of 1.36 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.22 a month ago based on nine recommendations.
Of the 11 recommendations deriving the current ABR, nine are Strong Buy, representing 81.82% of all recommendations. A month ago, Strong Buy represented 88.89%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SNN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 8 | 8 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 1 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.36 | 1.40 | 1.22 | 1.44 | 1.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/5/2024 | UBS | Graham Doyle | Hold | Strong Buy |
3/4/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/1/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
11/28/2023 | Not Identified | Not Identified | Not Available | Hold |
11/9/2023 | Goldman Sachs | Richard Felton | Not Available | Strong Buy |
10/31/2023 | Not Identified | Not Identified | Hold | Strong Buy |
10/4/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.36 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 11 |
Average Target Price | $32.00 |
LT Growth Rate | 13.30% |
Industry | Medical - Products |
Industry Rank by ABR | 96 of 252 |
Current Quarter EPS Est: | NA |